New scrutiny is being directed at Alzheimer’s drugs that focus on amyloid-targeting, as a recent Cochrane review challenges their effectiveness. This evaluation, conducted by a leading institution in medical evidence, suggests that these biological drugs offer minimal clinical benefits, coupled with high costs and significant risks of severe side effects. In response, the Czech company H2 Global Group has proposed an alternative approach using molecular hydrogen to the governments of all 27 EU member states.
On April 16, 2026, Cochrane released a systematic review analyzing the effects of anti-amyloid monoclonal antibodies in patients with mild cognitive impairment and mild dementia due to Alzheimer’s disease. The review consolidated data from 17 clinical trials involving over 20,000 participants, concluding that the impact of these drugs is largely “trivial” and fails to meet the threshold of clinically meaningful benefits. Additionally, the review reported an increased incidence of brain swelling and microhemorrhages, known as ARIA.
Leading researcher Francesco Nonino from the IRCCS Institute of Neurological Sciences in Bologna noted that these medications do not lead to significant clinical improvement. The authors of the review stressed the need for future Alzheimer’s research to explore alternative treatment methods. Various media outlets have echoed these findings, with The Guardian describing the effect as “trivial” and The New York Times highlighting the intense debate over the clinical value of these drugs. Meanwhile, experts like Professor Robert Howard from University College London have critiqued the overly optimistic portrayal of these medications to patients and their families.
The high cost of these treatments, estimated at around €77,000 ($82,000 USD) annually per patient, has also led to reimbursement challenges in several European countries. H2 Global Group is advocating for a shift towards molecular hydrogen therapy combined with virtual reality cognitive rehabilitation, which is already implemented in over 40 European hospitals. This approach is based on a patented method targeting oxidative stress and neuroinflammation, alongside neurodegeneration, as an alternative to the amyloid hypothesis.
The company’s strategy, rooted in the patent “Prophylactic or Therapeutic Agent for Dementia,” seeks to employ gaseous hydrogen for treating Alzheimer’s-type dementia, even in cases where traditional methods have failed. With a clinical study underway, approved by the Ethics Committee of University Hospital Ostrava, H2 Global Group’s CEO David Maršálek sees this as a historic opportunity for the Czech Republic to contribute to addressing the global dementia epidemic. By leveraging innovative Czech-Japanese technology and fostering EU-wide collaboration, the initiative aims to provide a safe, accessible, and effective solution for millions of patients and their families.